Corporate

Ranbaxy gets Canada's nod to mkt anti-hypertension drug

Pharma company Ranbaxy Laboratories today said it has received the final approval of the Canadian drug regulator Therapeutic Products Directorate (TPD) to market and manufacture "Ran-Amlodipine tablets", used in treating hypertensions. - Teva Pharma recalls anti-anxiety drug Propofol - Zenotech wants independent valuation for Daiichi open offer">Zenotech wants independent valuation for Daiichi open offer - Madras HC halts Daiichi"s open offer for Zenotech - Medicine for all - Shasun to invest Rs 100 cr for setting up new Vizag plant - Ranbaxy recalls drug from US mkt The company has got the approval for Ran-Amlodipine (Amlodipine Besylate tablets) in 5 and 10 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement. "We look forward to marketing both strengths of Ran-Amlodipine tablets at affordable prices that will be beneficial to both the Canadian healthcare system, and most importantly to Canadian patients," RPCI President Paul Drake said. The total market for Amlodipine Besylate tablets in Canada is 456 million Canadian dollars.

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):